Share

Prof. Vito Michele Fazio

Biography

Professor V.M. Fazio graduated in Medicine and Surgery in 1985 and then specialized in oncology in 1989 at the Catholic University of the Sacred Heart. He is a professor of general and clinical pathology at theUniversità Campus Bio-Medico di Roma, associate professor since 1991, full professor MED/2006 – 04/A06 since 2. Director of the Specialization Schools in Microbiology and Virology and subsequently in Pathology and Clinical Biochemistry.
Since 2001 he has been director of the Laboratory of Molecular Medicine and Biotechnology, where studies are carried out in:
- Pathology, oncology, and molecular genetics: genetic and epigenetic markers in multifactorial, hereditary diseases, and tumors; epigenetic program, stemness, and neoplastic transformation; individual genetic variability: genetic and epigenetic variants; intratumor heterogeneity.
- Biotechnology and molecular medicine: gene transfer and gene therapy; DNA vaccines and targeted immunotherapy; targeted therapy; development of new molecular diagnostic approaches.
- Molecular-genetic oncology diagnostics: genetic markers for diagnosis, follow-up, prognosis, and treatment choice in solid and blood tumors; PDO organoid models.
- Industrial R&D with chemical, pharmaceutical, biotechnology, and biomedical companies.
From 2005 to 2017 he taught Applied Immunology at the Faculty of Molecular Biotechnology Sciences of the University of Bari.
From 1993 to 2025 he was Director of the Experimental Oncology Laboratory of the IRCCS “Casa Sollievo della Sofferenza” in San Giovanni Rotondo (FG) and from 2011 to 2015 Deputy Scientific Director of the same IRCCS.
In 2020, appointed head of the Onco-Hematological Genetics Unit at the Policlinico Univ. Campus Bio-Medico (on leave from 2021).
Since 2020, Director of the Institute of Translational Pharmacology of the CNR, Rome, L'Aquila, Cagliari, Palermo
Author of over 170 peer-reviewed scientific publications.
Inventor in 5 patents

Curriculum

1978-1985 Degree in Medicine and Surgery, Catholic University of the Sacred Heart in Rome (110 cum laude).
1981-83 Summer Student at NIH, National Cancer Institute, Bethesda (MD), USA. Laboratories: Tumor Cell Biology: RC Gallo (2 months: 1981, 1983); Molecular Biology I. Pastan, B. De Chrombrugge (2 months, 1982).
1985-1987 Post-doc Fellowship CNR Finalized Project Oncology, “Molecular Biology”, Institute of General Pathology, University “La Sapienza”, Rome
1985-1989 Specialization Diploma in Oncology, with Honors, Catholic University of the Sacred Heart,
Faculty of Medicine and Surgery of Rome.
1987-1992 CNR Researcher, Institute of Experimental Medicine, Rome
1989 "invited visiting scientist" Department of Microbiology and Immunology, Curriculum in Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, for a collaboration on the cloning of exogenous DNA sequences integrated into the genome of transgenic animals.
1990 “invited visiting scientist”, University of California San Francisco, Gladstone Foundation Laboratories, San Francisco, CA, USA, for studies on “sperm mediated DNA transfer”
1992-2006 Associate Professor of Molecular Pathology SC Catholic University, Faculty of Medicine “A. Gemini”, Rome,
1993-2025 Head of the Oncology Laboratory (formerly Gene Therapy and Molecular Pathology), IRCCS Hospital “Casa Sollievo della Sofferenza”, Opera di San Pio da Pietrelcina, San Giovanni, round (FG).
1998-1999 Appointed by Decree of the Secretary General of the Presidency of the Council of Ministers, to the "Working Group on Cloning", within the National Committee for Biosafety and Biotechnologies
1998-2001 Technical Advisory Committee of Tecnofarmaci SCpA (a consortium of the main pharmaceutical and biotechnology industries operating in Italy, for the development of innovative pharmaceutical research) as an expert for Oncology and Biotechnology.
Since 2006 Full Professor of General and Clinical Pathology MED/04 – 06/A2, Università Campus Bio-Medico di Roma
2006 Appointed by the Ministry of University and Research as expert for the "biotechnology" sector in the CIVR (Address Committee for Research Evaluation), Triennial Research Evaluation,
2011-2013 Appointed by the Board of Directors of the National Agency for the Evaluation of the University and Research System (ANVUR) ​​to the Group of Evaluation Experts (GEV) for area 06 - Medical Sciences, VQR 2004-2010.
2011-2015 Deputy Scientific Director, IRCCS for “genetic diseases, innovative therapies and regenerative medicine” Hospital “Casa Sollievo della Sofferenza”, Opera di San Padre Pio da Pietrelcina, San Giovanni Round, Fg
2012-2018 member of the Board of Directors of the High Technology District in the Human Health and Biotechnology sector ("Puglia technological district for human health and biotechnology, limited liability consortium company"), H-BIO Puglia scarl.
2014: Approval by the Executive Committee of theUniversità Campus Bio-Medico di Roma of the UOS of Onco-Hematological Genetics and appointment as head (on leave from 2021).
Since 2020, Director of the Institute of Translational Pharmacology of the CNR, main office Rome Tor Vergata, other offices in Rome AOSCF-CRTL, Palermo, Cagliari, L'Aquila.
2022-2025 Member of the Board of Directors of the public-private consortium CNCCS scarl, National Collection of Chemical Compounds, Pomezia
Since 2022 Appointed by the CNR and MiMIT (formerly MiSE), President of Panel VII, Life Sciences Sector, Sustainable Growth Fund, for the coordination and management of the evaluation of research and development projects, Legislative Decree "Growth 1" (Legislative Decree 22 June 2012, n. 83) (formerly FIT funds).

PUBLICATIONS

Cioce M, Gatti V, … & Fazio VM. Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6. INT J MOL SCI. 2024;25(10):5355.
Donzelli S, Cioce M, Sacconi A, … Fazio VM, … Piccolo S, Blandino G. A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions. VERY CANCER. 2022;21(1):152.
Cioce M, … & Fazio VM. Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma. J EXP CLIN CANCER RES. 2021;40(1):344.
Zhu B^, … & Fazio VM*, Gallucci M*, Landi MT*. The genomic and epigenomic evolutionary history of papillary renal cell carcinomas. NAT COMM. 2020; 11(1):3096.
Muscarella LA, … Capoluongo ED & Fazio VM. Automated Workflow for Somatic and Germline Next Generation Sequencing Analysis in Routine Clinical Cancer Diagnostics. CANCERS. 2019;11(11).
M De Robertis, … J Garcia-Foncillas & VM Fazio. EphB2 stem-related and EphA2 progression-related miRNA-based networks in progressive stages of CRC evolution: clinical significance and potential miRNA drivers. MOL CANCER (2018) 17:169.
De Robertis M, Poeta ML, Signori E & Fazio VM. Current understanding and clinical utility of miRNAs regulation of colon cancer stem cells. SEM CANCER BIOL 53 (2018) 232–247.
De Robertis M, … Garcia-Foncillas J & Fazio VM. Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. CLIN CANCER RES. 2017;23(1):159-170.
Parrella P, … Maiello E, Murgo R & Fazio VM. Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients. VERY CANCER. 2014;13:142
Fernandez-Cuesta L, … Fazio VM, … Haas SA, Yatabe Y, Thomas RK. CD74-NRG1 fusions in lung adenocarcinoma. CANCER DISCOVERY 2014 4(4):415-22.
Seidel D, … Muscarella LA, Fazio VM, … Wolf J, Thomas RK. A genomics-based classification of human lung tumors. SCIENCE TRANSL MED 2013;5(209):209ra153.
Peifer M, … Muscarella LA, Fazio VM, … Haas S, Thomas RK. Integrative genome analyzes identify key somatic driver mutations of small-cell lung cancer. NAT GENET. 2012;44(10):1104-10.
De Robertis M, … Messrs E & Fazio VM. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J CARCINOG. 2011;10:9.
Volpe G, … Fazio VM, Saglio G. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. CANCER RES. 2007;67(11):5300-7.
Rinaldi M, … Iurescia S, Fioretti D, Rasi G & Fazio VM. Feasibilty of in utero DNA vaccination following naked gene transfer into pig fetal muscle: transgene expression, immunity and safety. VACCINES. 2006;24(21):4586-91.
Rinaldi M, … Saglio G & Fazio VM. Antibodies elicited by naked DNA vaccination against the CDR 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. CANCER RES. 2001;61(4):1555-62
Rinaldi M, … Farace MG & Fazio VM. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA. GENE THER. 2000;7(21):1795-801.
Fazio VM, Barrera G, Martinotti S, … Dianzani MU. 4-Hydroxynonenal, a product of cellular lipid peroxidation, which modulates c-myc and globin gene expression in K562 erythroleukemic cells. CANCER RES. 1992;52(18):4866-71.
Lavitrano M, Camaioni A, Fazio VM, Dolci S, Farace MG, Spadafora C. Sperm cells as vectors for introducing foreign DNA into eggs: genetic transformation of mice. CELL. 1989;57(5):717-23.

https://pubmed.ncbi.nlm.nih.gov/?term=fazio+vm&sort=date&size=200

Roles in the University

QUICK LINKS
[] magnifiercrossmenuchevron-downchevron-leftchevron-right